Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

PHASE3CompletedINTERVENTIONAL

Enrollment

654

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

January 31, 2007

Conditions

Essential Hypertension

Interventions

DRUG

Aliskiren

Trial Locations (2)

Investigative Centers

Novartis Pharmaceuticals, Basel